Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.68 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | TSPO | P30536 | 1/20 | 0.64 |
| ▸ | BRD2 | P25440 | 7/20 | 0.62 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.62 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.62 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | BRD1 | O95696 | 1/20 | 0.61 |
| ▸ | CCL2 | P13500 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | EP300 | Q09472 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976612 | 1.00 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL18463912 | 1.00 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL20687391 | 0.91 | BRD4 (0.56) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL27363394 | 0.91 | BRD4 (0.56) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL15182017 | 0.91 | BRD4 (0.56) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL23348676 | 0.89 | BRD4 (0.55) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL27338782 | 0.89 | BRD4 (0.58) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL25514002 | 0.89 | BRD4 (0.58) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL19453084 | 0.89 | BRD4 (0.55) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL23801126 | 0.88 | BRD4 (0.58) | BRD4DNERADORA3TSPOBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109707-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4584275-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | Halda Therapeutics Opco, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024054604-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
| US-11179373-B2 | Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(l,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases | UNIVERSITY OF DUNDEE (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210002296-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3683214-A1 | BRD4 INHIBITOR | Hinova Pharmaceuticals Inc. (CN) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019173224-A1 | DEUTERATED COMPOUNDS AND CHIMERAS AND USES THEREOF | BIOTHERYX, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3129378-B1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019055444-A1 | BET BROMODOMAIN PROTEIN DEGRADERS WITH CLEAVABLE LINKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018144789-A1 | FUSED 1,4-DIAZEPINES AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018052949-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002296-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | BRD4 941/4885DNER 2144/4885ADORA3 4716/4885 |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | BRD4 146/4885DNER 398/4885ADORA3 2030/4885 |
| US-11179373-B2 | Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(l,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases | BRD4, BRD3, BET1 | BRD4 1/4885DNER 894/4885ADORA3 4221/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | BRD4 623/4885DNER 1686/4885ADORA3 2010/4885 |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | VHL, HMBS, BRCA1 | BRD4 47/4885DNER 354/4885ADORA3 2102/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | BRD4 941/4885DNER 2144/4885ADORA3 4716/4885 |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | HAVCR2, CD4, MAVS | BRD4 1704/4885DNER 3472/4885ADORA3 3390/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | BRD4 3327/4885DNER 2973/4885ADORA3 2024/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | BRD4 2/4885DNER 690/4885ADORA3 4656/4885 |
| US-20260109707-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRDT | BRD4 1/4885DNER 1376/4885ADORA3 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.